FIELD: peptide chemistry.
SUBSTANCE: invention relates to acetylcholine receptor inhibitory peptides and uses thereof, wherein phages with high binding affinity for acetylcholine receptors are screened using random peptide recombinant phages and acetylcholine receptor binding peptides are selected using phage DNA. The acetylcholine receptor binding affinity and acetylcholine receptor inhibition effect has been confirmed using the selected peptides, and confirmed through modifications of peptides, peptide sites and sequences that are vital for binding to acetylcholine receptors.
EFFECT: acetylcholine receptor inhibitory peptides are expected to be in accordance with the present invention will be used in the development of a cosmetic composition for smoothing wrinkles, a drug for the prevention or treatment of acetylcholine receptor-associated diseases, and a health-improving food product for their alleviation.
10 cl, 39 dwg, 13 tbl, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED Α1-Α2 DOMAINS OF NON-NATURAL NKG2D LIGANDS THAT BIND TO NON-NATURAL NKG2D RECEPTORS | 2019 |
|
RU2815278C2 |
| MODIFIED MITOCHONDRIA AND THEIR USE | 2019 |
|
RU2811467C2 |
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
| ANTIBODIES AGAINST PROGRAMMED CELL DEATH LIGAND 1 AND THEIR USE | 2020 |
|
RU2786235C1 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| ANTI-HUMAN ANGIOPOIETIN-LIKE 4 PROTEIN ANTIBODIES | 2010 |
|
RU2580045C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| NEOANTIGENS AND THEIR APPLICATION METHODS | 2017 |
|
RU2773273C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| ANTIBODY-DRUG CONJUGATES INCLUDING ANTIBODY AGAINST HUMAN DLK1 AND THEIR USE | 2020 |
|
RU2801630C2 |
